 Adicet Bios Inc. ACET, -13.13 stock tumbled about 38 in premarket trading on Monday after the company shared data from a Phase 1 clinical trial evaluating the companys investigational CAR-T therapy in patients with relapsed or refractory B-cell non-Hodgkins lymphoma. Its too early for a true overall response rate, complete response, and 6-month CR rate, but profile continues to be promising, Wedbush analysts told investors on Monday morning. 